SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).
Carlos López LópezMariona CalvoJuan Carlos CámaraBeatriz García-ParedesCarlos Gómez-MartinAna María LópezRoberto Pazo-CidJavier SastreRicardo YayaJaime FeliuPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.
Keyphrases
- minimally invasive
- coronary artery bypass
- end stage renal disease
- lymph node
- prognostic factors
- public health
- newly diagnosed
- magnetic resonance imaging
- mental health
- chronic kidney disease
- pet ct
- peritoneal dialysis
- stem cells
- high resolution
- south africa
- rectal cancer
- computed tomography
- mesenchymal stem cells
- ultrasound guided
- drug induced